Compare QNC & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNC | KMDA |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | Canada | Israel |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.7M | 488.6M |
| IPO Year | 2026 | 2013 |
| Metric | QNC | KMDA |
|---|---|---|
| Price | $2.64 | $8.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 524.5K | 55.5K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $6.35 |
| 52 Week High | $3.41 | $9.35 |
| Indicator | QNC | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 42.53 |
| Support Level | $2.03 | $7.96 |
| Resistance Level | N/A | $8.40 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 72.38 | 41.25 |
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.